ZIM Laboratories Ltd receives Marketing Authorization for Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules in Portugal, Europe

ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The Company has state-of-the-art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms, aiming to enhance patient convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The Company is pleased to announce today that INFARMED (Portugal) - the Portuguese National Authority of Medicines and Health Products - has granted Marketing Authorization (MA) for ZIM's Central Nervous System (CNS) product "Dimethyl Fumarate 120 mg & 240 mg Modified Release Capsules," in Portugal to its wholly owned European subsidiary, SIA ZIM Laboratories Limited.

This authorisation will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities.

Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM's proprietary technology and is bioequivalent to the Innovator's product.

According to IQVIA, the EU market size for this product in 2023 was approximately USD 800 MN while UK contributed 200 MN USD. Other markets (Ex USA & Japan) contributed 42 MN USD.

Shares of Zim Laboratories Ltd was last trading in BSE at Rs. 84.77 as compared to the previous close of Rs. 81.00. The total number of shares traded during the day was 22359 in over 563 trades.

The stock hit an intraday high of Rs. 85.00 and intraday low of 82.71. The net turnover during the day was Rs. 1887645.00.

Source : Equity Bulls

Keywords

ZimLaboratories INE518E01015 Pharmaceuticals SIAZIMLaboratories INFARMED Portugal MarketingAuthorization DimethylFumarate ModifiedReleaseCapsules